Anchiano Tx (formerly Biocancell) is a biotechnology company specializing in the development of gene targeted cancer therapies. By targeting only the cancerous cells having the specific genes the treatment is safe and does not affect the surrounding tissue. Anchiano’s lead product BC-819 is targeted for the treatment of patients with Non Muscle Invasive Bladder Cancer who are either unresponsive to or have failed the standard treatment protocol. Anchiano’s completed several clinical trials which show the therapy to be safe and efficient.
There is a significant, unmet need in the market as no new drugs or therapies were introduced to the field since 1998 and there are supply issues with the current first line of treatment.